MedTrace Logo

Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism

NCT02938910 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2016-10-19

No results posted yet for this study

Summary

Animal models have demonstrated the role of aldosterone in left ventricular remodeling involving fibrosis, apoptosis and hypertrophy. Myocardial fibrosis is a risk factor for serious arrhythmia and sudden death in ischemic and idiopathic hypertrophic heart disease. It is accepted that patients with primary aldosteronism have a higher prevalence of LV hypertrophy , arterial involvement and increased cardiovascular risk. In humans, a link has been demonstrated between aldosterone and heart failure as well as the benefit of the administration of an anti -aldosterone drug to lower mortality in this population , regardless of blood pressure level . The administration of spironolactone ( aldosterone ) in hypertensive rats has prevented the occurrence of aortic fibrosis . Plasma aldosteronism in humans has been associated with inflammation, fibrosis and aortic stiffness . However, primary aldosteronism is generally associated with so-called secondary hypertension . Chronic hypertension alone is a recognized etiological factor of myocardial hypertrophy ( myocardial fibrosis very advanced ) . The purpose of this study is to investigate the effects of MRI hyperaldosteronism on the heart.

Conditions

  • Primary Hyperaldosteronism
  • Secondary Hyperaldosteronism
  • Essential Hypertension
  • Healthy

Interventions

OTHER

non interventional study

Non invasive imaging study without interventional procedures

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Elie MOUSSEAUX, MD, PhD · Assistance publique des hopitaux de Paris

  • Alban REDHEUIL, MD,PhD · Assistance publique des hopitaux de Paris

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02938910 on ClinicalTrials.gov